A cell-based quadrivalent influenza vaccine (Flucelvax Quad) is available on the private market in Australia in 2021. This vaccine is propagated in cell culture rather than in the conventional hens’ eggs. The cell-based vaccine has similar safety and efficacy to existing influenza vaccines and offers a useful alternative.
Influenza is a seasonal infectious disease that circulates most widely in the colder months (in Australia, April to October). Most people with influenza recover without serious complications. However, serious illness, hospitalisation and death can occur.1,2 The populations most vulnerable to severe disease include older adults, young children, pregnant women and people with certain chronic medical conditions.3